Montreal, Quebec, Canada Pendopharm appeared to be the Corporate Investor, which was created in 1983. The leading representative office of defined Corporate Investor is situated in the Montreal. The venture was found in North America in Canada.
Among the most successful fund investment fields, there are Pharmaceutical, Biotechnology. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Ireland. Among the various public portfolio startups of the fund, we may underline Sublimity Therapeutics Besides, a startup needs to be aged 11-15 years to get the investment from the fund.
The usual cause for the fund is to invest in rounds with 1 partaker. In the next rounds fund is usually obtained by OrbiMed, Longitude Capital, HBM Healthcare Investments AG.
The top activity for fund was in 2014. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year.
| Fund Name | Location |
| AHR Growth Partners | Chicago, Illinois, United States |
| Bailey Southwell & Co | Brentwood, Tennessee, United States |
| Cathay Capital Private Equity | France, Ile-de-France, Paris |
| Franklin Street Partners | Chapel Hill, North Carolina, United States |
| Jingyuewenhua | - |
| Kotobna | Egypt, Texas, United States |
| Matrixport | Central, Central Region, Singapore |
| Med-Metrix | Montvale, New Jersey, United States |
| Michelin | Auvergne, Auvergne-Rhône-Alpes, France |
| Omnis Mundi | Frankfurt, Germany, Hessen |
| Quadrille Capital | France, Ile-de-France, Paris |
| Soridec | France, Languedoc-Roussillon, Montpellier |
| Startup Edmonton | Alberta, Canada, Edmonton |
| Synetro Group | Chicago, Illinois, United States |
| TL Ventures | Pennsylvania, United States, Wayne |
| Toyo Tsushin Kogyo | Japan, Yamanashi, Yamanashi Prefecture |
| Uxin | Beijing, Beijing, China |
| Wingspan Ventures | California, Menlo Park, United States |
| Withfounders | Italy, Lombardia, Milano |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 